| P2093 | author name string | John E Pimanda | |
| | Anchit Khanna | |
| P2860 | cites work | CIP2A expression is increased in prostate cancer | Q21198842 |
| | Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence | Q24306834 |
| | Identification of PP2A complexes and pathways involved in cell transformation | Q24316472 |
| | CIP2A inhibits PP2A in human malignancies | Q24319683 |
| | CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle | Q24622357 |
| | Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 |
| | Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. | Q24813382 |
| | Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells | Q26852510 |
| | Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells | Q28299365 |
| | CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice | Q28590389 |
| | A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 |
| | Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells. | Q33636463 |
| | Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. | Q33712856 |
| | Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer | Q33835127 |
| | Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis | Q33895872 |
| | CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis | Q34138056 |
| | Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. | Q34138916 |
| | Therapy-Induced Senescence in Cancer | Q34212773 |
| | Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome | Q34577215 |
| | A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins | Q34609728 |
| | Modelling Myc inhibition as a cancer therapy | Q34811008 |
| | MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. | Q34983172 |
| | CIP2A is associated with human breast cancer aggressivity | Q34996768 |
| | CIP2A influences survival in colon cancer and is critical for maintaining Myc expression | Q35009096 |
| | High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer | Q35034737 |
| | Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. | Q35055737 |
| | Prognostic role of CIP2A expression in serous ovarian cancer | Q35263210 |
| | CIP2A is a target of bortezomib in human triple negative breast cancer cells | Q36245640 |
| | Involvement of PP2A in viral and cellular transformation | Q36318172 |
| | CIP2A protein expression in high-grade, high-stage bladder cancer | Q36530648 |
| | Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. | Q36609038 |
| | Regulation of cell adhesion by PP2A and SV40 small tumor antigen: an important link to cell transformation | Q36637948 |
| | Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells | Q36805842 |
| | Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors | Q36972697 |
| | Multiple pathways regulated by the tumor suppressor PP2A in transformation | Q37105971 |
| | Pro-senescence therapy for cancer treatment | Q37893959 |
| | Phosphatases: providing safe passage through mitotic exit | Q37900486 |
| | The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells | Q37980870 |
| | Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. | Q38160825 |
| | Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands | Q38228491 |
| | Increase in CIP2A expression is associated with doxorubicin resistance. | Q38478005 |
| | CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. | Q38982120 |
| | Expression and prognostic significance of CIP2A in cutaneous malignant melanoma | Q39039799 |
| | Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition. | Q39043713 |
| | CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion | Q39098575 |
| | CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma | Q39218849 |
| | Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma | Q39239414 |
| | Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. | Q39358186 |
| | CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells | Q39395326 |
| | Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells | Q39470889 |
| | Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells | Q39490308 |
| | Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein | Q39541598 |
| | ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells | Q39569073 |
| | Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. | Q39577867 |
| | CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells | Q39664633 |
| | Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types | Q39748970 |
| | CIP2A expression is elevated in cervical cancer | Q39757518 |
| | c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle | Q42115767 |
| | CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes | Q42500610 |
| | Clinical implications of CIP2A protein expression in breast cancer | Q43448302 |
| | CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma | Q43459677 |
| | Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. | Q44938943 |
| | CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis | Q45278609 |
| | CIP2A is a predictor of poor prognosis in colon cancer | Q48733192 |
| | CIP2A overexpression is associated with c-Myc expression in colorectal cancer. | Q50969099 |
| | PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. | Q53275436 |
| | Mutational analysis of MYC in common epithelial cancers and acute leukemias. | Q53592467 |
| | CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. | Q54298803 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 525-532 | |
| P577 | publication date | 2015-01-13 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers | |
| P478 | volume | 138 | |